NCT03856632Active, not recruitingPhase 4
Liraglutide Effect in Atrial Fibrillation
Novel Medical Adjunctive Therapy to Catheter Ablation For Atrial Fibrillation (AF)
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 25 Feb 2019
- Start date
- 18 Mar 2019
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- University of Miami
- Diseases
- Atrial fibrillation
- NCT number
- NCT03856632
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 60
- From 18 Mar 2019 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior ablation for atrial fibrillation
- Patients with a serious medical condition (for example, recent cancer with chemotherapy or radiation therapy within 4 weeks before entering the study) who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Known contraindications to Liraglutide, such as the previous history of pancreatitis or medullary thyroid carcinoma
Other illness
- Patients not appropriate candidates for catheter ablation such as those with AF due to acute or chronic precipitating medical conditions, for example, hypothyroidism and hyperthyroidism, significant pulmonary disease, pulmonary embolism, left atrial thrombus, class IV heart failure)
- Personal or family history of multiple endocrine neoplasias
- Known serious hypersensitivity reaction to Liraglutide
- Type 1 diabetes, defined by American Diabetes Association criteria, history of diabetic ketoacidosis, pancreas or beta-cell transplantation, or diabetes due to pancreatitis or pancreatectomy
Lab values
- Patients using, glitazones, sodium-glucose transporters 2 inhibitors (SGLT2i), other GLP-1 analogs, or DPP4 inhibitors
- Poorly controlled type 2 diabetes with HbA1c \> 10%
Other
- Inability to sign an informed consent
- Patients with longstanding persistent atrial fibrillation of more than 3 years
- Patients with a life expectancy \<1 year
- Pregnant women
- Women who are breast-feeding or intend to become pregnant
Who the study is looking for
- Male and female, age 18 or older
- Persistent AF defined as continuous AF sustained beyond 7 days (or AF with the decision to cardiovert before 7 days of enrollment or Paroxysmal AF defined as recurrent AF (≥2 episodes) that terminates spontaneously within 7 days
- BMI ≥27 kg/m2
- Patient wishes to undergo a catheter ablation procedure for the treatment of atrial fibrillation
- Receiving follow-up care at the University of Miami
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Miami Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
Related publications
- The Liraglutide Effects in Atrial Fibrillation (LEAF) Study.JACC Clin Electrophysiol · 2026 · PMID 42159524
This page is information, not medical advice. Discuss any trial with your doctor.